Business Description
MannKind Corp
NAICS : 325412
SIC : 2834
ISIN : US56400P7069
Share Class Description:
MNKD: Ordinary SharesTotal Employee Number:
592Compare
Compare
Traded in other countries / regions
MNKD.USANNFN.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2004-07-28Description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | -0.09 | |||||
Debt-to-Equity | -4.92 | |||||
Debt-to-EBITDA | 21.56 | |||||
Interest Coverage | 0.15 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.52 | |||||
Beneish M-Score | -1.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 42 | |||||
3-Year Book Growth Rate | 44.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.99 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.28 | |||||
9-Day RSI | 45.4 | |||||
14-Day RSI | 48.08 | |||||
3-1 Month Momentum % | 7.42 | |||||
6-1 Month Momentum % | 19.21 | |||||
12-1 Month Momentum % | -12.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.72 | |||||
Quick Ratio | 1.41 | |||||
Cash Ratio | 0.78 | |||||
Days Inventory | 138.9 | |||||
Days Sales Outstanding | 28.6 | |||||
Days Payable | 40.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -15.02 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.39 | |||||
Operating Margin % | 1.85 | |||||
Net Margin % | -11.08 | |||||
EBITDA Margin % | 3.9 | |||||
FCF Margin % | -4.61 | |||||
OCF Margin % | -2.05 | |||||
ROA % | -6.87 | |||||
ROIC % | 1.52 | |||||
3-Year ROIIC % | 22.3 | |||||
ROC (Joel Greenblatt) % | -0.43 | |||||
ROCE % | -0.08 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 112.04 | |||||
PS Ratio | 3.13 | |||||
EV-to-EBIT | -3704.8 | |||||
EV-to-EBITDA | 97.29 | |||||
EV-to-Revenue | 3.79 | |||||
EV-to-Forward-Revenue | 3.33 | |||||
EV-to-FCF | -82.33 | |||||
Price-to-GF-Value | 0.53 | |||||
Price-to-Median-PS-Value | 0.45 | |||||
Earnings Yield (Greenblatt) % | -0.03 | |||||
FCF Yield % | -1.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MNKD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MannKind Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 393.63 | ||
| EPS (TTM) ($) | -0.13 | ||
| Beta | 1.2015 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 72.62 | ||
| 14-Day RSI | 48.08 | ||
| 14-Day ATR ($) | 0.197748 | ||
| 20-Day SMA ($) | 4.00975 | ||
| 12-1 Month Momentum % | -12.92 | ||
| 52-Week Range ($) | 2.23 - 6.51 | ||
| Shares Outstanding (Mil) | 321.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MannKind Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MannKind Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 09:00 | In 180 days | ||
| Annual report for 2026 | 2027-02-26 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 09:00 | In 67 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 66 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 3.96 (+3.66%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 3.96 (+3.66%) | ||
| U.S. FDA Approval of Furoscix ReadyFlow Autoinjector | 2026-07-24 09:00 | 3.89 (+4.29%) | ||
| Guidance call for 2026 | 2026-06-03 09:20 | 3.43 (-1.72%) | ||
| U.S. FDA Approval of Afrezza in Pediatrics | 2026-05-29 16:30 | 3.64 (+1.96%) |
Show
Entries
MannKind Corp Frequently Asked Questions
What is MannKind Corp(MNKD)'s stock price today?
The current price of MNKD is $3.96. The 52 week high of MNKD is $6.51 and 52 week low is $2.23.
When is next earnings date of MannKind Corp(MNKD)?
The next earnings date of MannKind Corp(MNKD) is 2026-11-05 Est..
Does MannKind Corp(MNKD) pay dividends? If so, how much?
MannKind Corp(MNKD) does not pay dividend.
Press Release
Articles on MannKind Corp
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth
Aug 06, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers